Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2019.60.166
Interleukin 1 level, cognitive performance, and severity of depressive symptoms in patients treated with systemic anticancer therapy: a prospective study
Justyna Jasionowska
; Department of Adult Psychiatry,Medical University of Lodz, Lodz, Poland
Monika Talarowska
; Department of Adult Psychiatry,Medical University of Lodz, Lodz, Poland
Ewa Kalinka
; Department of Oncological Surgery and Breast Diseases, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
Aleksandra Skiba
; Department of Adult Psychiatry,Medical University of Lodz, Lodz, Poland
Janusz Szemraj
; Department of Medical Biochemistry, Medical University of Lodz, Lodz, Poland
Iwona Mikołajczyk
; Sub-unit of Diagnostics and Oncological Therapy, Department of Chemotherapy, Regional Oncological Centre, Voivodeship Specialist Hospital, Lodz, Poland
Sažetak
Aim To assess the relationship between cognitive functions,
severity of depressive symptoms, and expression of
interleukin 1 (IL)-1 in patients treated with systemic anticancer
therapy.
Methods This prospective study, conducted in 2017-2018,
involved 55 patients (56% men) subjected to systemic
anticancer therapy. Forty-one patients had lung cancer
(74.55%) and 14 had breast cancer (25.45%). Patients’ mean
age was 55.5 ± 9.3 (from 26 to 65 years). Neuropsychological
tests were conducted twice: on the day of qualifying
for the study before the start of chemotherapy and after
the end of the full treatment cycle. We assessed patients’
cognitive functioning using Trail Making Test A&B (TMT),
Stroop Color-Word Interference Test, and Verbal Fluency
Test (VFT). Severity of depressive symptoms and the level
of IL-1 expression were also examined.Results After chemotherapy, patients had significantly
lower expression of IL-1α (P < 0.005) and IL-1β (P < 0.001) at
the protein level. They also had lower severity of depressive
symptoms (borderline significant, P = 0.063), needed more
time to complete the first part of the Stroop test (P = 0.03),
and had worse score on the first part of the VFT (P < 0.001).
Before chemotherapy there was a significant negative correlation
between IL-1β expression and the speed at which
the first part of the TMT test was completed.
Conclusions The severity of depressive symptoms after
chemotherapy was lower than before chemotherapy. Patients’
cognitive performance did not significantly deteriorate
after chemotherapy, except the performance at the
first part of the Stroop test and the first part of the VFT.
Ključne riječi
Hrčak ID:
240024
URI
Datum izdavanja:
15.4.2019.
Posjeta: 566 *